{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:51Z","timestamp":1789186131243,"version":"build-2803163510"},"reference-count":28,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1253\/circrep.cr-26-0177","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:10:49Z","timestamp":1784844649000},"page":"1531-1539","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatment"],"prefix":"10.1253","volume":"8","author":[{"given":"Kotaro","family":"Hamamoto","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminari","family":"Tatsugami","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sartiani L, Bucciantini M, Spinelli V, Leri M, Natalello A, Nosi D, et al. Biochemical and electrophysiological modification of amyloid transthyretin on cardiomyocytes. <i>Biophys J<\/i> 2016; 111: 2024\u20132038.","DOI":"10.1016\/j.bpj.2016.09.010"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Manral P, Reixach N. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: Insights into early events of non-fibrillar tissue damage. <i>Biosci Rep<\/i> 2015; 35: e00172, doi:10.1042\/BSR20140155.","DOI":"10.1042\/BSR20140155"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Donnellan E, Wazni OM, Saliba WI, Hanna M, Kanj M, Patel DR, et al. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. <i>Am J Cardiol<\/i> 2020; 128: 140\u2013146.","DOI":"10.1016\/j.amjcard.2020.05.021"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. <i>Circulation<\/i> 2009; 120: 1203\u20131212.","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. <i>Eur Heart J<\/i> 2015; 36: 2585\u20132594.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Martens P, Hanna M, Valent J, Mullens W, Ives L, Kwon DH, et al. Electrical dyssynchrony in cardiac amyloidosis: Prevalence, predictors, clinical correlates, and outcomes. <i>J Card Fail<\/i> 2022; 28: 1664\u20131672.","DOI":"10.1016\/j.cardfail.2022.07.046"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. <i>J Am Coll Cardiol<\/i> 2016; 68: 1014\u20131020.","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. <i>Eur Heart J<\/i> 2018; 39: 2799\u20132806.","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eguchi C, Kawano H, Nishizawa RH, Yoshimuta T, Ohno C, Kojima S, et al. Comparing effects of tafamidis in controlling left ventricular and left atrial strains in patients with wild-type transthyretin amyloid cardiomyopathy. <i>Circ Rep<\/i> 2025; 7: 562\u2013567.","DOI":"10.1253\/circrep.CR-25-0066"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Izumiya Y, Kuyama N, Hanatani S, Matsuzawa Y, Usuku H, Yamamoto E, et al. Real-world clinical evidence with tafamidis in patients with transthyretin amyloid cardiomyopathy: A contemporary review. <i>Circ Rep<\/i> 2025; 7: 599\u2013603.","DOI":"10.1253\/circrep.CR-25-0092"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nakamura M, Imamura T, Hori M, Ushijima R, Joho S, Kinugawa K, et al. Initial experience with tafamidis treatment for transthyretin amyloid cardiomyopathy. <i>Circ Rep<\/i> 2020; 2: 420\u2013424.","DOI":"10.1253\/circrep.CR-20-0062"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shahi K, Miller RJH, Dykstra S, Feng Y, Howlett JG, Jimenez-Zepeda V, et al. Longitudinal changes in multiple cardiac biomarkers in transthyretin amyloidosis cardiomyopathy patients treated vs untreated with tafamidis. <i>CJC Open<\/i> 2025; 7: 1190\u20131197.","DOI":"10.1016\/j.cjco.2025.05.012"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: A meta-analysis. <i>JACC Cardiovasc Imaging<\/i> 2020; 13: 1299\u20131310.","DOI":"10.1016\/j.jcmg.2020.03.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. <i>Circ J<\/i> 2020; 84: 1610\u20131671.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, et al. A Statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2019; 84: 15\u201317.","DOI":"10.1253\/circj.CJ-19-0811"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lockwood PA, Le VH, O\u2019Gorman MT, Patterson TA, Sultan MB, Tankisheva E, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4\u00d720-mg capsules in healthy volunteers. <i>Clin Pharmacol Drug Dev<\/i> 2020; 9: 849\u2013854.","DOI":"10.1002\/cpdd.789"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, et al. AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram. Part III: Intraventricular conduction disturbances: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: Endorsed by the International Society for Computerized Electrocardiology. <i>Circulation<\/i> 2009; 119: e235\u2013e240, doi:10.1161\/CIRCULATIONAHA.108.191095.","DOI":"10.1161\/CIRCULATIONAHA.108.191095"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kitagawa T, Tatsugami F, Yokomachi K, Akiyama Y, Fujii Y, Awai K. Native myocardial T1 value in predicting 1-year outcomes in patients with nonischemic dilated cardiomyopathy experiencing recent heart failure. <i>Int Heart J<\/i> 2022; 63: 531\u2013540.","DOI":"10.1536\/ihj.21-801"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ikegami Y, Kitagawa T, Sada Y, Okamoto D, Hamamoto K, Tatsugami F, et al. Myocardial T1 mapping, left ventricular parameters, and cardiac biomarkers in wild-type transthyretin amyloid cardiomyopathy before and after tafamidis treatment. <i>Circ Rep<\/i> 2025; 7: 198\u2013206.","DOI":"10.1253\/circrep.CR-24-0170"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Argir\u00f2 A, Zampieri M, Mazzoni C, Fumagalli C, Baccini M, Mattei A, et al. Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis. <i>ESC Heart Fail<\/i> 2025; 12: 809\u2013818.","DOI":"10.1002\/ehf2.14684"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kuyama N, Izumiya Y, Takashio S, Usuku H, Tabira A, Oguni T, et al. Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretin amyloid cardiomyopathy. <i>Circ J<\/i> 2025; 89: 421\u2013431.","DOI":"10.1253\/circj.CJ-24-0733"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fischer K, Lellouche N, Damy T, Martins R, Clementy N, Bisson A, et al. Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis. <i>ESC Heart Fail<\/i> 2022; 9: 740\u2013750.","DOI":"10.1002\/ehf2.13663"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Donnellan E, Wazni OM, Saliba WI, Baranowski B, Hanna M, Martyn M, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. <i>J Cardiovasc Electrophysiol<\/i> 2019; 30: 2427\u20132432.","DOI":"10.1111\/jce.14180"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Kawahara Y, Kanazawa H, Takashio S, Tsuruta Y, Sumi H, Kiyama T, et al. Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy. <i>EP Europace<\/i> 2023; 25: euad105, doi:10.1093\/europace\/euad105.","DOI":"10.1093\/europace\/euad105"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. <i>JACC Cardiovasc Imaging<\/i> 2019; 12: 810\u2013819.","DOI":"10.1016\/j.jcmg.2018.02.006"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Endo J, Tsujita K, Izumi C, Yano T, Kitaoka H, Sekijima Y, et al. Efficacy and safety of acoramidis in Japanese adults with symptomatic transthyretin amyloid cardiomyopathy. <i>Circ Rep<\/i> 2026; 8: 788\u2013796.","DOI":"10.1253\/circrep.CR-26-0013"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tahara N, Raizner A, Chen Y, Mercuri MF, Minamisawa M; Phase 3 Japan Study Investigators. Efficacy of acoramidis in adults with transthyretin amyloid cardiomyopathy: Propensity score comparison between a single-arm open-label phase 3 trial in Japan and a global double-blind phase 3 trial. <i>Circ Rep<\/i> 2026; 8: 797\u2013806.","DOI":"10.1253\/circrep.CR-25-0304"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/9\/8_CR-26-0177\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:26:02Z","timestamp":1789183562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/9\/8_CR-26-0177\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0177","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"CR-26-0177"}}